About GeoVax
GeoVax is a publicly listed company based in Smyrna (United States) founded in 1988. Developer of human vaccines for cancer and infectious diseases. The company has 17 employees. GeoVax offers products and services including Gedeptin and GEO-CM04S1. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is GEOVAX LABS, INC. Its competitors include Adaptive Biotechnologies, Moderna and C4 Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
GeoVax was founded in 1988 and is headquartered in Smyrna, United States. Operations focus on biotechnology, specifically the development of vaccines for cancer and infectious diseases through a DNAMVA platform that generates non-infectious virus-like particles from recipient cells. Current programs target Ebola, HIV, and cancer immunotherapy, with preclinical efforts including HIV-clade B and C preventive vaccines, platform development for cancer treatments, and monovalenttetravalent hemorrhagic fever virus vaccines.
- Headquarters Smyrna, United States
- Employees 17
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website geovax.com
- Social LinkedIn X YouTube
- Legal Name Geovax Labs, Inc.
- Annual Revenue$2.49 M (USD)-37.06as on Dec 31, 2025
- Net Profit-$21.46 M (USD)14.11as on Dec 31, 2025
- EBITDA-$21.57 M (USD)13.89as on Dec 31, 2025
- Latest Funding Round$10M (USD), Post-IPO
Jan 2022
- InvestorsNIH
& 2 more
- Employee Count17
Products & Services of GeoVax
GeoVax offers a comprehensive portfolio of products and services, including Gedeptin and GEO-CM04S1.
Therapy for advanced head and neck cancers through clinical trials.
Next-generation vaccine targeting COVID-19 in high-risk groups.
Apps and channels of GeoVax
its YouTube channel GeoVax Labs has 90 subscribers and 24 videos.
Videos from GeoVax
The most watched videos on GeoVax's YouTube channel, GeoVax Labs (90 subscribers). Click a video to play it here.
More on GeoVax Labs.
Funding Insights of GeoVax
- Total Rounds 33
- Last Round Post-IPO — $10M
- First Round $100,000
(Jun 2002)
- Investors Count 3
Latest 10 of 33 funding rounds of GeoVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $10M | Post-IPO | – | – | – |
| Feb 2021 | $495,000 | Post-IPO | – | – | – |
| Jan 2021 | Grant | – | – | ||
| Jan 2021 | $299,927 | Grant | – | – | |
| Oct 2020 | $1.5M | Post-IPO | – | – | – |
| Jun 2020 | $2.4M | Post-IPO | – | – | – |
| Nov 2019 | $700,000 | Post-IPO | – | – | – |
| Jul 2019 | $3.26M | Post-IPO | – | – | – |
| Sep 2018 | $2.44M | Grant | – | – | |
| Apr 2018 | $299,820 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in GeoVax
GeoVax has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for GeoVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GeoVax
14 people are tracked at GeoVax (10 in leadership, 4 in board & advisors); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
David A. Dodd | Chairman, President & Ceo, Geovax Labs, Inc. | Leadership |
Arban Domi | Director, Vaccine Development | Leadership |
John Niles | Head of Commercial Development & Operations | Leadership |
Ashley Zuniga, PhD | Director, Project Management | Biotech | Leadership |
Kelly McKee | Chief Medical Officer | Leadership |
Mark Reynolds | CFO | Leadership |
Kathleen A. Walker | Senior Director, Vaccine Development | Leadership |
Tom O'Brien | Vice President, Head of Quality | Leadership |
Harriet L. Robinson | Director HIV Vaccines | Leadership |
John W. Sharkey, PhD | VP, Bus. Dev. (June 2022-present) / Head Bus. Dev. (Consultant Jan 2021 - June 2022) | Leadership |
Randal D. Chase | Director | Board & advisors |
John N. Spencer, Jr. | Director | Board & advisors |
Dean G. Kollintzas | Director | Board & advisors |
Robert T. Mcnally | Director | Board & advisors |
Complete people profiles for GeoVax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GeoVax
GeoVax is a publicly listed company on the NASDAQ with ticker symbol GOVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 2020
- Listed onNASDAQ: GOVX
- Listed entityGeoVax Labs, Inc.
- Exchange sectorHealth technology
- ISINUS3736787058
- Share price$0.27 (-5.92% on the day) · 2026-10-13
- Market capitalisation$2.7M
- EPS (diluted, trailing year)$-13.93
- Volume (last session)227,627
Financials of GeoVax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.5M | -$21.5M | -$21.6M |
| 2024 | $4.0M | -$25.0M | -$25.1M |
| 2023 | -$26.0M | -$26.7M | |
| 2022 | -$14.0M | -$14.1M | |
| 2021 | $385,500 | -$18.6M | -$18.7M |
Detailed financial statements for GeoVax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GeoVax
4 dated milestones of GeoVax across 34 years, from founding to its latest funding, stage changes and deals.
- Founded GeoVax is founded.
- Funding First funding round of $100K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $10.0M.
Competitors of GeoVax
GeoVax has 3 listed competitors in our database, 3 of them funded. They include Adaptive Biotechnologies, Moderna and C4 Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of GeoVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GeoVax
The website of GeoVax (geovax.com) receives about 6.8K visits a month and ranks #3,124,816 among all websites worldwide, #4,116 in Biotechnology and Pharmaceuticals.
- Monthly visits6.8K
▲ 7.2% vs previous month
- Unique visitors2.7K
per month
- Global rank#3,124,816
among all websites
- Category rank#4,116
Health · Biotechnology and Pharmaceuticals
- Bounce rate54%
- Pages per visit1.8
- Average visit20 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with GeoVax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hvtn.org | hvtn.org | 100% | #4,654,286 | – | |
| genocea.com | 100% | View details | |||
| medicago.com | 99% | View details | |||
| vbivaccines.com | 99% | 11.4K | #3,481,567 | View details | |
| gilead.com | 69% | 576.5K | #103,109 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for GeoVax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as GeoVax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Geovax
Complete news archive for GeoVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeoVax
GeoVax was founded in 1988 and raised its 1st funding round 14 years after it was founded.
GeoVax is headquartered in Smyrna, United States.
GeoVax has 17 employees.
Annual revenue of GeoVax is $2.49M as on Dec 31, 2025.
GeoVax was founded in 1988 and is headquartered in Smyrna, United States. Operations focus on biotechnology, specifically the development of vaccines for cancer and infectious diseases through a DNAMVA platform that generates non-infectious virus-like particles from recipient cells. Current programs target Ebola, HIV, and cancer immunotherapy, with preclinical efforts including HIV-clade B and C preventive vaccines, platform development for cancer treatments, and monovalenttetravalent hemorrhagic fever virus vaccines.
GeoVax's top competitors include Moderna, C4 Therapeutics and Adaptive Biotechnologies.
GeoVax offers Gedeptin and GEO-CM04S1.
Yes, GeoVax is publicly traded on NASDAQ under the ticker symbol GOVX.
GeoVax has 3 investors. Key investors include NIH, HHS, and U.S. Department of Defense.
GeoVax operates through Geovax Labs, Inc..